EC approves PADCEV and KEYTRUDA combo for advanced urothelial cancer treatment
Astellas Pharma Inc. has announced a significant milestone in cancer treatment with the European Commission (EC's) approval of PADCEV (enfortumab vedotin) combined with KEYTRUDA (pembrolizumab). ... Read More
Breakthrough in cancer treatment: China approves PADCEV for advanced urothelial cancer
China's National Medical Products Administration (NMPA) has granted approval for PADCEV (enfortumab vedotin) to treat locally advanced or metastatic urothelial cancer (la/mUC) in adult patients. ... Read More
Astellas Pharma embraces HPE Asset Upcycling Services for environmental stewardship
In a significant stride towards sustainable IT solutions, Hewlett Packard Enterprise (HPE) has partnered with Astellas Pharma Inc., marking a pivotal initiative in the global ... Read More